Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation

J Heart Lung Transplant. 2022 Sep;41(9):1285-1293. doi: 10.1016/j.healun.2022.06.001. Epub 2022 Jun 6.

Abstract

Background: It is unknown whether pulmonary arterial hypertension (PAH) risk stratification instruments could be helpful to support the decision to list a patient for lung transplantation (LT). Our aim was to evaluate contemporary risk assessment tools in a cohort of PAH patients listed for LT.

Methods: Consecutive PAH patients (without pulmonary veno-occlusive disease or unrepaired congenital heart disease) listed for LT at the French Pulmonary Hypertension Reference Center between January 2006 and December 2018 were included. At the time of listing, risk stratification was assessed using the ESC/ERS criteria, the REVEAL Lite 2 score and the COMPERA 2.0 method. The primary end point was overall survival after LT listing. Secondary outcome measures were mortality on waiting list and posttransplant survival.

Results: One hundred and two patients were enrolled (mean age 38 ± 13 years, 69% females). Overall survival after listing was 72%, 58% and 46% at 1, 3 and 5 years respectively. Survival after LT listing was lower in "high-risk" patients according to the ESC/ERS criteria (p = 0.0001) and the REVEAL Lite 2 score (p = 0.04). The COMPERA 2.0 method discriminated post-listing survival of patients at high-risk, intermediate-high and intermediate-low risk (p = 0.04). The proportion of patients requiring urgent transplantation and extracorporeal life support as a bridge to transplantation was higher in the "high-risk" patients. Posttransplant survival was significantly lower in "high-risk" patients according to the ESC/ERS criteria (p = 0.0004).

Conclusions: High-risk PAH patients at the time of LT listing have poor outcomes, suggesting that LT should be considered earlier in the course of PAH remaining refractory to triple combination therapy with a parenteral prostacyclin.

Keywords: lung transplantation; pulmonary arterial hypertension; right heart failure; risk stratification; survival.

MeSH terms

  • Adult
  • Epoprostenol
  • Familial Primary Pulmonary Hypertension
  • Female
  • Humans
  • Lung Transplantation*
  • Male
  • Middle Aged
  • Pulmonary Arterial Hypertension* / surgery
  • Retrospective Studies
  • Risk Assessment

Substances

  • Epoprostenol